Literature DB >> 25161042

The role of nuclear imaging in pulmonary hypertension.

H Ohira1, R S Beanlands, R A Davies, L Mielniczuk.   

Abstract

Pulmonary hypertension (PH) is a disease characterized by a chronic elevation of pulmonary artery pressure from various causes. Pulmonary artery hypertension (PAH) is one of subtype which results in premature death often as a result of right ventricular (RV) dysfunction. In spite of the recent progress in novel cardiac imaging techniques and new drugs for PAH, there remain significant unresolved issues including a need for earlier diagnosis, refinement of risk stratification, and monitoring the effects of treatment. Cardiac and pulmonary imaging with transthoracic echocardiography (TTE) with Doppler, magnetic resonance imaging (MRI), and computed tomography (CT) are done routinely in many clinical centers. However, routine and emerging nuclear techniques may have a pivotal role of assessment of the patient with PH, and is currently the subject of significant research. Potential Roles for Nuclear Imaging in the Evaluation of the PH Patient: (1) Evaluation of cardiac structure and function (RNA) (non-nuclear techniques would include TTE, CT, and MRI). (2) Functional imaging. This includes the use of ventilation-perfusion scintigraphy (V/Q scan) to diagnose chronic thromboembolic pulmonary hypertension (CTEPH), 123l-metaiodobenzylguanidine (MIBG) imaging to evaluate the cardiac sympathetic nervous system (non-nuclear techniques include invasive right heart catheterization and TTE). (3) Measurement of RV perfusion (with gated SPECT studies). (4) Evaluation of cardiac and pulmonary metabolism (PET scans). This review article will summarize the pathophysiology, classification, natural history, and diagnostic approach of PH. Current and emerging nuclear techniques will be discussed under the four themes of evaluation of structure, functional imaging, flow, and metabolism. These will be compared to current and emerging nuclear and non-nuclear diagnostic tests in the evaluation and management of patients with PH. We will also discuss research applications exploring new insights into flow and metabolism in the right heart and lung and the application of new radioligands.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25161042     DOI: 10.1007/s12350-014-9960-y

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  112 in total

1.  Validation study on the accuracy of echocardiographic measurements of right ventricular systolic function in pulmonary hypertension.

Authors:  Takahiro Sato; Ichizo Tsujino; Hiroshi Ohira; Noriko Oyama-Manabe; Asuka Yamada; Yoichi M Ito; Chisa Goto; Taku Watanabe; Shinji Sakaue; Masaharu Nishimura
Journal:  J Am Soc Echocardiogr       Date:  2012-01-09       Impact factor: 5.251

2.  Utility of right ventricular free wall speckle-tracking strain for evaluation of right ventricular performance in patients with pulmonary hypertension.

Authors:  Yuko Fukuda; Hidekazu Tanaka; Daisuke Sugiyama; Keiko Ryo; Tetsuari Onishi; Hiroyuki Fukuya; Munenobu Nogami; Yoshiharu Ohno; Noriaki Emoto; Hiroya Kawai; Ken-Ichi Hirata
Journal:  J Am Soc Echocardiogr       Date:  2011-07-19       Impact factor: 5.251

Review 3.  Assessment of the right ventricle with radionuclide techniques.

Authors:  D S Schulman
Journal:  J Nucl Cardiol       Date:  1996 May-Jun       Impact factor: 5.952

4.  Tricuspid annular displacement predicts survival in pulmonary hypertension.

Authors:  Paul R Forfia; Micah R Fisher; Stephen C Mathai; Traci Housten-Harris; Anna R Hemnes; Barry A Borlaug; Elzbieta Chamera; Mary C Corretti; Hunter C Champion; Theodore P Abraham; Reda E Girgis; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2006-08-03       Impact factor: 21.405

5.  Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients.

Authors:  P J Currie; J B Seward; K L Chan; D A Fyfe; D J Hagler; D D Mair; G S Reeder; R A Nishimura; A J Tajik
Journal:  J Am Coll Cardiol       Date:  1985-10       Impact factor: 24.094

6.  Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension.

Authors:  Ronald J Raymond; Alan L Hinderliter; Park W Willis; David Ralph; Edgar J Caldwell; William Williams; Neil A Ettinger; Nicholas S Hill; Warren R Summer; Bennett de Boisblanc; Todd Schwartz; Gary Koch; Linda M Clayton; Maria M Jöbsis; James W Crow; Walker Long
Journal:  J Am Coll Cardiol       Date:  2002-04-03       Impact factor: 24.094

7.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

8.  Chronic thromboembolic pulmonary hypertension: evaluation with 64-detector row CT versus digital substraction angiography.

Authors:  Angela Reichelt; Marius M Hoeper; Michael Galanski; Marc Keberle
Journal:  Eur J Radiol       Date:  2008-05-06       Impact factor: 3.528

Review 9.  The interplay between MYC and HIF in cancer.

Authors:  Chi V Dang; Jung-whan Kim; Ping Gao; Jason Yustein
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

10.  Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments.

Authors:  Lan Zhao; Ali Ashek; Lei Wang; Wei Fang; Swati Dabral; Olivier Dubois; John Cupitt; Soni Savai Pullamsetti; Emanuele Cotroneo; Hazel Jones; Gianpaolo Tomasi; Quang-De Nguyen; Eric O Aboagye; Mona A El-Bahrawy; Gareth Barnes; Luke S Howard; J Simon R Gibbs; Willy Gsell; Jian-Guo He; Martin R Wilkins
Journal:  Circulation       Date:  2013-07-30       Impact factor: 29.690

View more
  4 in total

1.  Pharmacologic stress myocardial perfusion imaging in patients with pulmonary hypertension: What do we know, and what remains to be learned?

Authors:  Andrew Van Tosh; Kenneth J Nichols
Journal:  J Nucl Cardiol       Date:  2018-06       Impact factor: 5.952

2.  Dual-energy CT (DECT) lung perfusion in pulmonary hypertension: concordance rate with V/Q scintigraphy in diagnosing chronic thromboembolic pulmonary hypertension (CTEPH).

Authors:  Matthieu Masy; Jessica Giordano; Grégory Petyt; Claude Hossein-Foucher; Alain Duhamel; Maeva Kyheng; Pascal De Groote; Marie Fertin; Nicolas Lamblin; Jean-François Bervar; Jacques Remy; Martine Remy-Jardin
Journal:  Eur Radiol       Date:  2018-05-30       Impact factor: 5.315

3.  Detection and quantitation of right ventricular reversible perfusion defects by stress SPECT myocardial perfusion imaging: A proof-of-principle study.

Authors:  Ayman A Farag; Jack Heo; Lindsey Tauxe; Pradeep Bhambhvani; Guido Germano; Paul Kavanagh; Ami E Iskandrian; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2017-07-06       Impact factor: 5.952

Review 4.  Pulmonary Hypertension in Intensive Care Units: An Updated Review.

Authors:  Armin Nowroozpoor; Majid Malekmohammad; Seyyed Reza Seyyedi; Seyed Mohammadreza Hashemian
Journal:  Tanaffos       Date:  2019-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.